Neuropsychiatric Symptoms and Microglial Activation in Patients with Alzheimer Disease
Authors: Cristiano Schaffer Aguzzoli, Pâmela C. L. Ferreira, Guilherme Povala, João Pedro Ferrari-Souza, Bruna Bellaver, Carolina Soares Katz, Hussein Zalzale, Firoza Z. Lussier, Francieli Rohden, Sarah Abbas, Douglas T. Leffa, Marina Scop Medeiros, Joseph Therriault, Andréa L. Benedet, Cécile Tissot, Stijn Servaes, Nesrine Rahmouni, Arthur Cassa Macedo, Gleb Bezgin, Min Su Kang, Jenna Stevenson, Vanessa Pallen, Ann Cohen, Oscar L. Lopez, Dana L. Tudorascu, William E. Klunk, Victor L. Villemagne, Jean Paul Soucy, Eduardo R. Zimmer, Lucas P. Schilling, Thomas K. Karikari, Nicholas J. Ashton, Henrik Zetterberg, Kaj Blennow, Serge Gauthier, Victor Valcour, Bruce L. Miller, Pedro Rosa-Neto, Tharick A. Pascoal
Journal: JAMA Network Open (2023)

Importance Neuropsychiatric symptoms are commonly encountered and are highly debilitating in patients with Alzheimer disease. Understanding their underpinnings has implications for identifying biomarkers and treatment for these symptoms. Objective To evaluate whether glial markers are associated with neuropsychiatric symptoms in individuals across the Alzheimer disease continuum. Design, Setting, and Participants This cross-sectional study was conducted from January to June 2023, leveraging data from the Translational Biomarkers in Aging and Dementia cohort at McGill University, Canada. Recruitment was based on referrals of individuals from the community or from outpatient clinics. Exclusion criteria included active substance abuse, major surgery, recent head trauma, safety contraindications for positron emission tomography (PET) or magnetic resonance imaging, being currently enrolled in other studies, and having inadequately treated systemic conditions. Main Outcomes and Measures All individuals underwent assessment for neuropsychiatric symptoms (Neuropsychiatry Inventory Questionnaire [NPI-Q]), and imaging for microglial activation ([ 11 C]PBR28 PET), amyloid-β ([ 18 F]AZD4694 PET), and tau tangles ([ 18 F]MK6240 PET). Results Of the 109 participants, 72 (66%) were women and 37 (34%) were men; the median age was 71.8 years (range, 38.0-86.5 years). Overall, 70 had no cognitive impairment and 39 had cognitive impairment (25 mild; 14 Alzheimer disease dementia). Amyloid-β PET positivity was present in 21 cognitively unimpaired individuals (30%) and in 31 cognitively impaired individuals (79%). The NPI-Q severity score was associated with microglial activation in the frontal, temporal, and parietal cortices (β = 7.37; 95% CI, 1.34-13.41; P = .01). A leave-one-out approach revealed that irritability was the NPI-Q domain most closely associated with the presence of brain microglial activation (β = 6.86; 95% CI, 1.77-11.95; P = .008). Furthermore, we found that microglia-associated irritability was associated with study partner burden measured by NPI-Q distress score (β = 5.72; 95% CI, 0.33-11.10; P = .03). Conclusions and Relevance In this cross-sectional study of 109 individuals across the AD continuum, microglial activation was associated with and a potential biomarker of neuropsychiatric symptoms in Alzheimer disease. Moreover, our findings suggest that the combination of amyloid-β– and microglia-targeted therapies could have an impact on relieving these symptoms.